William Blair Starts Zura Bio (ZURA) at Outperform

Zura Bio Limited (NASDAQ:ZURA) is one of the 10 High Growth Stocks Insiders Are Buying.

On July 8, 2026, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating. The firm sees potential for the dual mechanism of action of tibulizumab to drive “differentiated efficacy” in two ongoing Phase 2 studies in hidradenitis suppurativa and systemic sclerosis.

On June 29, Zura Bio announced several tibulizumab program updates. The company completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS, exceeding the target enrollment with 247 participants enrolled. Zura also remained on track to complete enrollment of the Phase 2 TibuSURE trial of tibulizumab in adults with early diffuse cutaneous SSc in early July, with the trial already exceeding its target enrollment of 80 participants.

Morgan Stanley Raises its Price Target on Alnylam (ALNY)

Topline data from TibuSHIELD are expected in the fourth quarter of 2026, while topline data from TibuSURE are expected in H1 2027. Zura also plans to initiate a Phase 2 study in a third immune-mediated indication by year-end 2026 and announce the new indication before study initiation. Also on June 29, Zura said it had cash and cash equivalents of $225.6M as of March 31, 2026, and continues to expect its existing cash to fund planned operations through at least the end of 2028.

Zura Bio Limited (NASDAQ:ZURA) develops medicines for autoimmune and inflammatory disorders in the United States.

While we acknowledge the risk and potential of ZURA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZURA and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1